AbbVie Q2 2026: adj. EPS $3.65 (+22.9% YoY), revenue $16.99B (+10.2%); announces $10.9B Apogee acquisition

AbbVie Inc.

GAAP diluted EPS $2.03 (+290.4% YoY); adjusted diluted EPS $3.65 (+22.9% YoY); includes $0.17 IPR&D impact.
Net revenues $16.99B (+10.2% reported, +9.5% operational); Immunology $8.786B (+15.1%) led by Skyrizi $5.505B (+24.4%).
Neuroscience $3.228B (+20.3%); Oncology $1.650B (-1.5%); Aesthetics $1.282B (+0.3%).
Announces definitive agreement to acquire Apogee Therapeutics for ~$10.9B equity value; expected close Q3 2026.
Updates 2026 adj. EPS guidance to $13.87-$14.07 (from $13.91-$14.11); includes $0.14 dilutive impact from Apogee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.